Publications
Max Planck Research Group Jachimowicz
Journal Article (23)
2023
Journal Article
Biallelic variants in CRIPT cause a Rothmund-Thomson-like syndrome with increased cellular senescence. Genetics in Medicine, 100836, p. 100836 (2023)
2022
Journal Article
Distinct genetically-determined origins of Myd88/Bcl2-driven aggressive lymphoma rationalize targeted therapeutic intervention strategies. Blood Cancer Discov (2022)
Journal Article
11 (20) (2022)
Genomic Amplification of UBQLN4 Is a Prognostic and Treatment Resistance Factor. Cells
Journal Article
24 (1), p. 41 (2022)
Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer. Breast Cancer Res
Journal Article
Correspondence to: hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination. Infection (2022)
Journal Article
Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination. Infection, pp. 1 - 6 (2022)
2021
Journal Article
35 (12), pp. 3589 - 3593 (2021)
Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP. Leukemia
Journal Article
15 (4), pp. 1069 - 1087 (2021)
Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma. Mol Oncol
Journal Article
12 (140), pp. 1679 - 1693 (2021)
Biallelic variants in YRDC cause a developmental disorder with progeroid features. Human Genetics 2020
Journal Article
9 (10), p. 2287 (2020)
Targeting DNA Repair, Cell Cycle, and Tumor Microenvironment in B Cell Lymphoma. Cells
Journal Article
106 (6), pp. 1684 - 1692 (2020)
Analysis of the tumor microenvironment by whole-slide image analysis identifies low B cell content as a predictor of adverse outcome in advanced-stage classical Hodgkin lymphoma treated with BEACOPP. Haematologica 2019
Journal Article
34 (3), pp. 771 - 786 (2019)
ATM activity in T cells is critical for immune surveillance of lymphoma in vivo. Leukemia
Journal Article
10 (1), p. 3485 (2019)
MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nat Commun
Journal Article
6 (2), p. 1575692 (2019)
UBQLN4 promotes non-homologous end joining by repressing DNA end-resection. Mol Cell Oncol
Journal Article
18 (13), pp. 1423 - 1434 (2019)
DNA double-strand break repair pathway choice - from basic biology to clinical exploitation. Cell Cycle
Journal Article
176 (3), pp. 505 - 519 e22 (2019)
UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors. Cell 2018
Journal Article
9 (1), p. 727 (2018)
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun 2014
Journal Article
132 (3-4), pp. 274 - 8 (2014)
The challenging aspects of managing adolescents and young adults with Hodgkin's lymphoma. Acta Haematol
Journal Article
28 (4), pp. 331 - 43 (2014)
Multi-specific antibodies for cancer immunotherapy. BioDrugs
Journal Article
4 (5), pp. 592 - 605 (2014)
A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discov